Monitor cash burn rate and initiation of AP-SA02 Phase 3 trial. The $25M loan buys time but adds significant interest expense and secured debt, increasing risk of dilution or default if milestones slip. Stock likely to react negatively to continued losses and going-concern overhang.
ARMP drugs
ARMP drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $8.20entry
- T+1 · 6mo ago 0.00%α −0.01% · $8.20
- T+5 · 6mo ago +0.37%α +1.08% · $8.23
- T+20 · 5mo ago −7.56%α −6.70% · $7.58
- T+60 · 3mo ago −43.90%α −47.49% · $4.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 development, while reporting a Q1 2026 net loss of $115.3M (largely non-cash fair value charges) and cash of only $4.8M pre-loan. The loan extends runway but adds significant leverage, and the company's ability to achieve Phase 3 milestones remains uncertain given ongoing cash burn.
Key Financial Metrics
Key Facts
- Entered $25M secured term loan with Innoviva at 14.0% interest, maturing January 11, 2029
- Q1 2026 net loss of $115.3M vs $6.5M in Q1 2025, driven by $101M non-cash change in convertible loan fair value
- Cash and cash equivalents of $4.8M at March 31, 2026, down from $8.7M at December 31, 2025
- Operating loss widened to $8.8M from $8.2M in Q1 2025
- FDA granted Fast Track and QIDP designations for AP-SA02; Phase 3 study expected H2 2026
- Loan is secured by substantially all assets and includes covenants restricting operations
Financial Impact
$25M debt added at 14% interest; net loss of $115.3M in Q1 2026
Risk Factors
- High cash burn with only $4.8M pre-loan; new debt at 14% interest rate
- Going concern risk remains; total stockholders deficit of $311.6M
- Clinical and regulatory uncertainty for AP-SA02 Phase 3
- Secured loan covenants may restrict operational flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-060299 |
| Document: armp-20260512xex99d1.htm | 0001104659-26-060299 |
| Document: armp-20260512x8k.htm | 0001104659-26-060299 |
| Document: 0001104659-26-060299-index-headers.html | 0001104659-26-060299 |
| Document: 0001104659-26-060299-index.html | 0001104659-26-060299 |
| Document: 0001104659-26-060299.txt | 0001104659-26-060299 |
| 8-K Data (Synthetic) | 0001104659-26-060299 |
Track record
6 reports on ARMP
0 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +1.98% at T+1 after the Jul 20, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
- Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
- May 13, 202626w ago 8-K Bearish 6/10 Viewing Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
- Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers